The British Journal of Psychiatry · 2013 · 24 citations · 11 references
MedicinePharmacologyPsychiatryNeuropharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDopaminergic PharmacologyGlutamatergic PharmacologySchizophrenia PharmacotherapyAntipsychotic ActionAntipsychotic EfficacyAntipsychotic Side EffectsAtypical Antipsychotic TreatmentGlutamatergic DysfunctionGlutamatergic NeurotransmissionGlutamatergic Synapses
Currently available antipsychotic drugs target dopaminergic neurotransmission. Many patients do not respond fully to these treatments, and there has been considerable effort to investigate alternative targets. Here we summarise the rationale and recent evidence supporting efforts to develop glutamatergic antipsychotic drugs.
11
Bita Moghaddam, Barbara W. Adams, Anita Verma et al. · Journal of Neuroscience · 1997 · 1.8K citations · Full text
Medicine, Neuroscience, Pharmacology +14
Glutamate Receptor Dysfunction and Schizophrenia
John W. Olney · Archives of General Psychiatry · 1995 · 1.7K citations
Medicine, Neuroscience, Psychiatry +17
Ketamine activates psychosis and alters limbic blood flow in schizophrenia
Adrienne C. Lahti, Henry H. Holcomb, Deborah R. Medoff et al. · Neuroreport · 1995 · 440 citations
Medicine, Neuroscience, Psychiatry +17